Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS. (PubMed, J Neuromuscul Dis) - Aug 18, 2026 - "While amifampridine is the established first-line symptomatic treatment, longitudinal data regarding the evolution of therapeutic regimens over time and the use of immunosuppressive therapies remain limited...Immunosuppressive drug use-predominantly prednisolone and azathioprine -increased over time, reaching 44% after five years...Immunomodulatory therapies were introduced gradually and their use increased over time. Compared with autoimmune myasthenia gravis, immunomodulatory therapy was used less frequently during the early disease course of LEMS."
Journal • CNS Disorders • Immunology • Myasthenia Gravis • Oncology
|
|
Jan J G M Verschuuren; Linda Remijn-Nelissen; Martijn R Tannemaat; Romina Shahini; Teun van Gelder; Wisse R Bakker
|